Mesatone 1 percent. Mezaton solution: instructions for use. Pharmacokinetic information

Pilot plant "GNTsLS" (Ukraine), Branch "Pilot plant GNTsLS" (Ukraine)

pharmachologic effect

Vasoconstrictor.

Stimulates postsynaptic alpha-adrenergic receptors.

Biotransforms in the liver and gastrointestinal tract.

Excreted by the kidneys in the form of metabolites.

The action begins immediately after administration and continues for 20 (after intravenous injection) - 50 minutes (with subcutaneous injection) - 1-2 hours (after intramuscular injection).

Heart rate decreases, stroke output increases, systolic and diastolic blood pressure increases, and the pulse reflexively decreases.

OPSS is increasing.

Stimulates the brain and spinal cord.

Reduces blood flow - renal, skin, in the abdominal organs and extremities, increases - coronary.

Constricts pulmonary vessels and increases pressure in the pulmonary artery.

How a vasoconstrictor has an anticongestive effect:

• reduces swelling and hyperemia of the nasal mucosa, the severity of exudative manifestations, restores free breathing;
• lowers pressure in the paranasal cavities and middle ear.

Causes pupil dilation, normalizes intraocular pressure in open-angle forms of glaucoma.

Side effect

Headache, agitation, anxiety, irritability, weakness, dizziness, hypertension, bradycardia, arrhythmia, pain in the heart, respiratory depression, oliguria, acidosis, pale skin, tremor, paresthesia, local ischemia of the skin at the injection site, necrosis and eschar formation when contact with tissue or subcutaneous injection.

Indications for use

Subdural and inhalation anesthesia (to maintain adequate blood pressure and prolong subdural anesthesia), local anesthesia (as a vasoconstrictor), acute circulatory failure, anaphylaxis, neurogenic shock, hypotension, incl. orthostatic, paroxysmal supraventricular tachycardia, reperfusion arrhythmias (Bertzold-Jarisch reflex), priapism, secretory prerenal anuria, iritis, iridocyclitis.

Contraindications

Hypersensitivity, severe arterial hypertension, ventricular tachycardia, tendency to vasospasms, bradycardia, shock during myocardial infarction, decompensated heart failure, conduction disorders, severe atherosclerosis, severe forms of coronary artery disease, damage to the cerebral arteries, arterial hypertension, acute pancreatitis and hepatitis, hyperthyroidism, peripheral thrombosis and mesenteric arteries, prostatic hypertrophy, pregnancy, children (up to 15 years) and old age.

Directions for use and dosage

In case of acute decrease in blood pressure, it is administered intravenously at a dose of 0.1 - 0.3 - 0.5 ml of a 1% solution in 40 ml of glucose solution or isotonic sodium chloride solution.

1 ml of a 1% solution is injected dropwise into 250 - 500 ml of glucose solution.

0.3 - 1 ml of a 1% solution is prescribed under the skin or intramuscularly (for adults).

Highest single doses for adults subcutaneously and intramuscularly:

• one-time - 0.01,
• daily - 0.05g,
• into a vein: single - 0.005,
• daily - 0.025g.

Overdose

It manifests itself as ventricular extrasystole and short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, and a significant increase in blood pressure.

Treatment:

• IV administration of alpha-blockers (for example,
• phentolamine) and beta-blockers (for rhythm disturbances).

Interaction

Oxytocin, MAO inhibitors, tricyclic antidepressants, ergot alkaloids, sympathomimetics increase the pressor effect, and the latter also increase arrhythmogenicity.

Alpha-blockers (phentolamine), phenothiazines, furosemide and other diuretics prevent vasoconstriction.

Beta-blockers neutralize cardiac stimulating activity; in the presence of reserpine, arterial hypertension is possible (due to depletion of catecholamine reserves in adrenergic neurons, sensitivity to sympathomimetics increases).

special instructions

To stimulate labor, it is not recommended to use it in combination with oxytocin-containing drugs (severe persistent hypertension and damage to cerebral vessels with the development of hemorrhagic stroke in the postpartum period are possible).

During the treatment period, ECG, blood pressure, pulmonary artery wedge pressure, cardiac output, blood circulation in the extremities and at the injection site should be monitored.

In case of arterial hypertension, it is necessary to maintain SBP at a level of 30-40 mmHg. lower than usual.

Before starting or during therapy, correction of hypovolemia, hypoxia, acidosis, and hypercapnia is required.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent rhythm disturbances require cessation of treatment.

To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion.

The infusion is resumed if the SBP decreases to 70-80 mmHg.

During therapy, potentially dangerous activities that require rapid motor and mental reactions are excluded.

Registration number

Trade name of the drug: Mezaton

International nonproprietary name:

Dosage form:

Compound:

Description: transparent colorless liquid.

Pharmacotherapeutic group:

ATX Code C01CA06

Pharmacological properties
Pharmacodynamics
Synthetic alpha 1-adrenergic stimulant, which has little effect on cardiac beta-blockers; is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and an increase in blood pressure (BP) with possible reflex bradycardia. Compared to norepinephrine and epinephrine, the increase in blood pressure is less dramatic, but lasts longer (it is less susceptible to the action of catechol-O-methyltransferase) and does not cause an increase in minute blood volume. The action begins immediately after administration and continues for 20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular injection).

Pharmacokinetics.
Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.

Indications for use
Collapse, arterial hypotension (associated with decreased vascular tone), in preparation for surgery and during operations, vasomotor and hay rhinitis, intoxication, as a vasoconstrictor during local anesthesia

Contraindications
Hypersensitivity to the drug, hypertrophic obstructive cardiomyopathy (including asymmetric septal hypertrophy), pheochromocytoma, tachyarrhythmia, atrial and/or ventricular fibrillation, metabolic acidosis, hypercapnia, hypoxia, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe stenosis aortic orifice, acute myocardial infarction, porphyria. congenital deficiency of glucose-6-phosphate dehydrogenase, tendency to vascular spasms, pregnancy, lactation, age under 18 years (efficacy and safety have not been established).

Carefully: Prinzmetal's angina, history of occlusive vascular diseases, including arterial thromboembolism, atherosclerosis, thromboangiitis obliterans (Buerger's disease), frostbite, diabetic endarteritis, Raynaud's disease, thyrotoxicosis, old age, diabetes mellitus, under general anesthesia (fluorotane), impaired renal function .

Directions for use and doses
Mezaton is administered intravenously, subcutaneously, intramuscularly, intranasally. In case of collapse, the drug is administered, as a rule, intravenously in doses of 0.1-0.3-0.5 ml of a 1% solution, diluted with 20 ml of 5% - 20% dextrose (glucose) solutions or 0.9% sodium chloride solution. The administration is carried out slowly, the administration is repeated if necessary. With the drip method, 1 ml of a 1% solution of Mezaton is administered in 250-500 ml of a 5% solution of dextrose (glucose). Adults are administered subcutaneously and intramuscularly in doses of 0.3-1 ml of a 1% solution.

In order to narrow the vessels of the mucous membranes of the nasal cavity and reduce the severity of inflammation, 0.25-0.5% solutions are instilled or the mucous membranes are lubricated with these solutions. To local anesthetics (per 10 ml of anesthetic solution) add 0.3-0.5 ml of 1% Mezaton solution.

Higher doses for adults: intravenous - single 0.005 g, daily - 0.025 g; subcutaneously and intramuscularly - one-time 0.01 g, daily - 0.05 g.

Side effect
From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.

From the gastrointestinal tract: dyspeptic symptoms;

From the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage;

Others: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.

Overdose
Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.

Treatment: intravenous administration of alpha-blockers (phentolamine) and beta-blockers (for heart rhythm disturbances).

Interaction with other drugs
Phenothiazines, alpha-blockers (phentolamine), Furosemide and other diuretics reduce the hypertensive effect.

Monoamine oxidase inhibitors, oxytocin, ergot alkaloids, tricyclic antidepressants, furazolidine, procarbazine, selegiline, adrenostimulants increase the pressor effect, and the latter also increase arrhythmogenicity.

Beta-blockers reduce cardiac stimulating activity, and with reserpine, arterial hypertension is possible (due to depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases).

special instructions
During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.

Before starting or during therapy, correction of hypovolemia, hypoxia, acidosis, and hypercapnia is required.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment. To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion. The infusion is resumed if systolic blood pressure decreases to 70-80 mmHg. Art.

During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).

Release form
Solution for injection 10 mg/ml.

1 ml in ampoules, enclosed in 10 pieces together with instructions for use and an ampoule scarifier in a cardboard pack.

Storage conditions
List B. In a place protected from light and out of reach of children, at a temperature not exceeding 25°C.

Best before date
3 years.

Do not use the drug after the expiration date indicated on the package!

Conditions for dispensing from pharmacies
On prescription.

Manufacturing company
LLC "Experimental plant "GNTsLS" Address: Ukraine, 61057, Kharkov, st. Vorobyova, 8

Alpha adrenergic agonist

Active substance

Phenylephrine hydrochloride (phenylephrine)

Release form, composition and packaging

1 ml - ampoules (10) - cardboard packs.

pharmachologic effect

Alpha1-adrenergic stimulant, which has little effect on beta-adrenergic receptors of the heart; is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and increased blood pressure (with possible reflex bradycardia). Compared with epinephrine, it increases blood pressure less sharply, but acts longer (less susceptible to the action of catechol-O-methyltransferase); does not cause an increase in minute blood volume.

The action begins immediately after administration and lasts for 5-20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular administration).

Pharmacokinetics

Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.

Indications

Parenterally:

• arterial hypotension;
• shock conditions (including traumatic, toxic);
• vascular insufficiency (including due to an overdose of vasodilators);
• as a vasoconstrictor during local anesthesia.

Intranasally:

• vasomotor and allergic rhinitis.

Contraindications

• hypersensitivity to the drug;
• hypertrophic obstructive cardiomyopathy;
• pheochromocytoma;
• ventricular fibrillation.

Carefully:

Metabolic acidosis, hypercapnia, hypoxia, angle-closure glaucoma, arterial hypertension, hypertension in the pulmonary circulation, hypovolemia, severe aortic stenosis, acute myocardial infarction, tachyarrhythmia, ventricular arrhythmia, occlusive vascular diseases (including a history) - arterial thromboembolism , atherosclerosis, thromboangiitis obliterans (Buerger's disease), Raynaud's disease, vascular tendency to spasms (including frostbite), diabetic endarteritis, thyrotoxicosis, diabetes mellitus, porphyria, glucose-6-phosphate dehydrogenase deficiency, combined use of monoamine oxidase inhibitors, with general anesthesia (fluorotane), impaired renal function, old age, age under 18 years (efficacy and safety have not been established).

Dosage

Intravenously slowly, in case of collapse - 0.1-0.3-0.5 ml of 1% solution, diluted in 20 ml of 5% dextrose solution or 0.9% solution. If necessary, the administration is repeated.

Intravenous drip - 1 ml of 1% solution in 250-500 ml of 5% dextrose solution.

Subcutaneously or intramuscularly, adults- 0.3-1 ml of 1% solution 2-3 times a day; children over 15 years old at arterial hypotension during spinal anesthesia- 0.5-1 mg/kg.

For constriction of blood vessels in the mucous membranes and reduction of inflammation lubricate or instill (solution concentrations - 0.125%, 0.25%, 0.5%, 1%).

At local anesthesia add 0.3-0.5 ml of 1% solution per 10 ml of anesthetic solution.

Higher doses for adults: subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 mg, daily - 25 mg.

Side effects

From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.

From the side of the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.

Others: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.

Overdose

Symptoms: ventricular extrasystole, short paroxysms of ventricular tachycardia, a feeling of heaviness in the head and limbs, a significant increase in blood pressure.

Treatment: intravenous administration of alpha-blockers (phentolamine) and (for heart rhythm disturbances).

Drug interactions

Mezaton reduces the antihypertensive effect of diuretics and antihypertensive drugs (methyldopa, mecamylamine, guanadrel, guanethidine).

Phenothiazines, alpha-blockers (phentolamine), and other diuretics reduce the hypertensive effect.

Monoamine oxidase inhibitors (furazolidone, procarbazine, selegiline), oxytocin, ergot alkaloids, tricyclic antidepressants, methylphenidate, adrenostimulants enhance the pressor effect and arrhythmogenicity of phenylephrine.

Beta-blockers reduce cardiac stimulating activity; in the presence of reserpine, arterial hypertension is possible (as a result of depletion of catecholamine reserves in adrenergic endings, sensitivity to adrenergic agonists increases). Inhalation drugs (chloroform, enflurane, halothane, isoflurane, methoxyflurane) increase the risk of severe atrial and ventricular arrhythmias, since they sharply increase the sensitivity of the myocardium to sympathomimetics.

Ergotamine, methylergometrine, oxytocin, doxapram increase the severity of the vasoconstrictor effect.
Reduces the antianginal effect of nitrates, which, in turn, can reduce the pressor effect of sympathomimetics and the risk of arterial hypotension (simultaneous use is possible depending on the achievement of the required therapeutic effect).

Thyroid hormones increase (mutually) the effect and the associated risk of coronary insufficiency (especially with coronary atherosclerosis).

special instructions

During the treatment period, ECG, blood pressure, minute blood volume, blood circulation in the extremities and at the injection site should be monitored.

In patients with arterial hypertension in case of drug-induced collapse, it is enough to maintain systolic blood pressure at a level lower than usual by 30-40 mm Hg.

Before or during therapy for shock conditions, correction of hypovolemia, hypoxia, acidosis and hypercapnia is mandatory.

A sharp increase in blood pressure, severe bradycardia or tachycardia, persistent cardiac arrhythmias require discontinuation of treatment.

To prevent a recurrent decrease in blood pressure after discontinuation of the drug, the dose should be reduced gradually, especially after long-term infusion.

The infusion is resumed if systolic blood pressure decreases to 70-80 mm Hg.

It should be borne in mind that the use of vasoconstrictors during labor to correct arterial hypotension or as additives to local anesthetics against the background of drugs that stimulate labor (vasopressin, ergotamine, ergometrine, methylergometrine) may lead to a persistent increase in blood pressure in the postpartum period.

With age, the number of adrenergic receptors sensitive to phenylephrine decreases. Monoamine oxidase inhibitors, increasing the pressor effect of sympathomimetics, can cause headaches, arrhythmia, vomiting, hypertensive crisis, therefore, when patients take monoamine oxidase inhibitors in the previous 2-3 weeks, the dose of sympathomimetics should be reduced.

Impact on the ability to drive vehicles and operate machinery

During therapy, you should not engage in hazardous activities that require rapid motor and mental reactions (including driving a car).

Pregnancy and lactation

Adequate and strictly controlled studies on humans and animals on the effect of the drug on pregnant women have not been conducted, there is no data on the excretion of the drug into breast milk, based on which, during pregnancy and during breastfeeding, the use of the drug is possible with caution, only under strict indications and under the supervision of a doctor , assessing the benefit-risk ratio.

Storage conditions and periods

Store in a place protected from light and out of reach of children at a temperature not exceeding 25°C. Shelf life - 3 years.

| Mesaton

Analogs (generics, synonyms)

Vizofrin, Nazol Baby, Nazol Kids, Neosynephrine-POS, Phenylephrine hydrochloride, Aurora Hot Sip, Adjicold, Adrianol, Aidrink, Axagrip, Alergomax, Amicitron, Anacold, Anticataral, Antiflu, Appamide Plus, Aspirin Complex, Astracitron, Bronchoril, Vibrocil, Vokasept , Glycodin, Gripout, b Gripgo, Gripcold-N, Griposan, Griposan Plus, Griposan Hot, Gripflu, Influnorm, Irifrin, Coldrin, Coldflu Extra, Coldfree, Combigripp, Combinex, Combinex-P, Lorraine, Lorkold, Maxicold, Midrimax, Neogrip , Neoflu 750, Nolgripp, Parafex, Prostudox, Radicold Plus, Rankof, Relief, Rinza, Rinikold, Pharmacitron, Flucoldex forte, Citric

Recipe (international)

Rp.: Sol. Mesatoni 1% 1 ml
D.t. d. N. 10 in ampull.
S. Dissolve the contents of the ampoule in 40 ml of 40% glucose solution. Administer intravenously, slowly.

Rp.: Sol. Mesatoni 1% 1 ml
D.t. d. N. 10 in ampull.
S. Inject 0.5-1 ml subcutaneously or intramuscularly.

Rp.: Sol. Mesatoni 1% 5 ml
D.S. Eye drops. 1-2 drops per day in both eyes.

Rp.: Sol. Mesatoni 0.25% 10 ml
D.S. Nasal drops.

Recipe (Russia)

Prescription form - 107-1/у

Active substance

Phenylephrine

pharmachologic effect

Alpha1-adrenergic stimulant, which has little effect on beta-adrenergic receptors of the heart. It is not a catecholamine (contains only one hydroxyl group in the aromatic ring). Causes constriction of arterioles and increased blood pressure (with possible reflex bradycardia). Compared to norepinephrine and epinephrine, it increases blood pressure less sharply, but acts longer (less susceptible to the action of catechol-O-methyltransferase). Does not cause an increase in minute blood volume.
The action begins immediately after administration and continues for 5-20 minutes (after intravenous administration), 50 minutes (with subcutaneous administration), 1-2 hours (after intramuscular administration). Metabolized in the liver and gastrointestinal tract (without the participation of catechol-O-methyltransferase). Excreted by the kidneys in the form of metabolites.

Mode of application

For adults: Intravenously slowly, in case of collapse - 0.1-0.3-0.5 ml of 1% solution, diluted in 20 ml of 5% dextrose solution or 0.9% sodium chloride solution. If necessary, the administration is repeated.
Intravenous drip - 1 ml of 1% solution in 250-500 ml of 5% dextrose solution. Subcutaneously or intramuscularly, adults - 0.3-1 ml of 1% solution 2-3 times a day; children over 15 years of age with arterial hypotension during spinal anesthesia - 0.5-1 mg/kg.

To narrow the vessels of the mucous membranes and reduce inflammation, lubricate or instill (solution concentrations - 0.125%, 0.25%, 0.5%, 1%).
For local anesthesia, add 0.3-0.5 ml of a 1% solution per 10 ml of anesthetic solution.

Higher doses for adults: subcutaneously and intramuscularly: single - 10 mg, daily - 50 mg; intravenously: single - 5 g, daily - 25 mg.

Indications

Parenterally:
- arterial hypotension;
— shock states (including traumatic, toxic);
- vascular insufficiency (including due to an overdose of vasodilators);
- as a vasoconstrictor during local anesthesia.

Intranasally:

- vasomotor and allergic rhinitis.

Contraindications

- hypersensitivity to the drug;
— hypertrophic obstructive cardiomyopathy;
- pheochromocytoma;
- ventricular fibrillation.
- metabolic acidosis
- hypercapnia
— hypoxia
- atrial fibrillation
- angle-closure glaucoma, arterial hypertension
- hypertension in the pulmonary circulation
- hypovolemia
- severe stenosis of the aortic mouth
- acute myocardial infarction
- tachyarrhythmia
- ventricular arrhythmia
- occlusive vascular diseases (including a history) - arterial thromboembolism atherosclerosis
- thromboangiitis obliterans (Buerger's disease)
- Raynaud's disease
- tendency of blood vessels to spasms (including during frostbite)
- diabetic endarteritis
- thyrotoxicosis, diabetes mellitus
- porphyria
- deficiency of glucose-6-phosphate dehydrogenase
- combined use of monoamine oxidase inhibitors
- under general anesthesia (fluorotane)
- renal dysfunction
- elderly age
- age under 18 years (efficacy and safety have not been established).

Side effects

- From the cardiovascular system: increased blood pressure, palpitations, ventricular fibrillation, arrhythmia, bradycardia, cardialgia.
- From the central nervous system: dizziness, fear, insomnia, anxiety, weakness, headache, tremor, paresthesia, convulsions, cerebral hemorrhage.
— Other: pallor of the facial skin, ischemia of the skin at the injection site, in isolated cases, necrosis and scab formation are possible when it enters the tissue or during subcutaneous injections, allergic reactions.

Release form

Solution for injection. 10 mg/1 ml: amp. 10 pieces.
Solution for injection 1 ml
phenylephrine hydrochloride 10 mg
1 ml - ampoules (10) - cardboard packs.

ATTENTION!

The information on the page you are viewing is created for informational purposes only and does not in any way promote self-medication. The resource is intended to provide healthcare workers with additional information about certain medications, thereby increasing their level of professionalism. The use of the drug "" necessarily requires consultation with a specialist, as well as his recommendations on the method of use and dosage of the medicine you have chosen.

Instructions for use:

Mezaton is a drug with vasoconstrictor and alpha-adrenomimetic effects.

Release form and composition

Mezaton is available in the form of an injection solution: transparent, colorless (1 ml in ampoules, 10 ampoules in a cardboard pack, complete with a ceramic cutting disc or ampoule scarifier).

Active ingredient: phenylephrine hydrochloride, 1 ml – 10 mg.

Auxiliary components: injection water and glycerin.

Indications for use

• Vascular insufficiency (including due to an overdose of vasodilators);
• Arterial hypotension;
• Allergic and vasomotor rhinitis;
• Shock conditions, including toxic and traumatic shock.

In addition, Mezaton is used during local anesthesia as a vasoconstrictor.

Contraindications

Absolute:

• Hypertrophic obstructive cardiomyopathy;
• Ventricular fibrillation;
• Pheochromocytoma;
• Hypersensitivity to the drug.

Relative (special care should be taken due to the risk of complications):

• Arterial hypertension, hypertension in the pulmonary circulation, atrial fibrillation, ventricular arrhythmia, acute myocardial infarction, severe aortic stenosis, angle-closure glaucoma, hypoxia, hypovolemia, hypercapnia, tachyarrhythmia, metabolic acidosis;
• Occlusive vascular diseases (including a history): Buerger's disease (thromboangiitis obliterans), atherosclerosis, Raynaud's disease, arterial thromboembolism, vascular tendency to spasms (including frostbite), porphyria, diabetes mellitus, glucose-6 deficiency phosphate dehydrogenase, thyrotoxicosis, diabetic endarteritis;
• Concomitant use of monoamine oxidase inhibitors (MAO);
• Functional kidney disorders;
• General fluorotane anesthesia;
• Age up to 18 years;
• Elderly age.

Pregnant and breastfeeding women can be prescribed Mezaton only according to strict indications, after assessing the balance of benefits and possible risks.

Directions for use and dosage

Mezaton solution is administered intravenously (stream or drip), intramuscularly or subcutaneously.

In case of collapse, it is administered intravenously in a slow stream at a dose of 0.1-0.3-0.5 ml, having previously diluted 20 ml of 0.9% sodium chloride solution or 5% dextrose solution. If necessary, another dose is administered.

The drug is administered intravenously in a dose of 1 ml, having previously diluted 250-500 ml of a 5% dextrose solution.

Mezaton is prescribed intramuscularly or subcutaneously for adults at a dose of 0.3-1 ml 2-3 times a day, for children over 15 years of age with arterial hypotension during spinal anesthesia - at a dose of 0.5-1 mg per kilogram of body weight.

To reduce inflammation and constriction of blood vessels in the mucous membranes, the drug (at concentrations of 0.125, 0.25, 0.5, 1%) is used for lubrication or instillation.

When performing local anesthesia, for every 10 ml of anesthetic solution, add 0.3-0.5 ml of a 1% Mezaton solution.

Maximum permissible doses for adults:

• Intravenous: single – 5 mg, daily – 25 mg;
• Intramuscular and subcutaneous: single dose – 10 mg, daily dose – 50 mg.

Side effects

• Cardiovascular system: increased blood pressure, rapid heartbeat, arrhythmia, ventricular fibrillation, cardialgia, bradycardia;
• Central nervous system: insomnia, fear, anxiety, dizziness, weakness, paresthesia, tremor, convulsions, headache, cerebral hemorrhage;
• Other: skin ischemia at the injection site, facial skin pallor; in isolated cases - allergic reactions, scab formation and necrosis (with subcutaneous injections and if the solution gets into the tissue).

special instructions

During treatment, it is necessary to monitor electrocardiogram indicators, blood pressure, blood circulation at the injection site and extremities, and minute blood volume.

Before or during treatment of shock conditions, correction of hypoxia, hypovolemia, hypercapnia and acidosis is required.

In the case of drug-induced collapse in patients with arterial hypertension, it is enough to maintain systolic blood pressure at a level lower than usual by 30-40 mmHg.

Persistent heart rhythm disturbances, severe tachycardia or bradycardia, and a sharp increase in blood pressure require discontinuation of Mezaton.

To prevent a repeated decrease in blood pressure after discontinuation of the drug, it is recommended to reduce the dose gradually, especially after long-term infusion. However, if systolic blood pressure decreases to 70-80 mm Hg, the infusion is resumed.

It should be borne in mind that vasoconstrictors used in addition to local anesthetics simultaneously with drugs that stimulate labor (ergotamine, vasopressin, methylergometrine, ergometrine), or intended to correct arterial hypotension during labor, may lead to a persistent increase in blood pressure in the postpartum period .

With age, the number of adrenergic receptors sensitive to phenylephrine decreases. MAO inhibitors, increasing the pressor effect of sympathomimetics, can contribute to the appearance of vomiting, the development of arrhythmia, headaches, and hypertensive crisis. For this reason, patients who have taken MAO inhibitors in the previous 2-3 weeks should have their sympathomimetic doses reduced.

During the period of treatment with Mezaton, it is necessary to refrain from engaging in activities that require speed of mental and motor reactions, including driving.

Drug interactions

Possible interaction reactions in case of simultaneous use of Mezaton and other drugs:

• Antihypertensive drugs, diuretics: reducing their hypotensive effect;
• Monoamine oxidase inhibitors (procarbazine, furazolidone, selegiline), tricyclic antidepressants, ergot alkaloids, adrenergic stimulants, methylphenidate, oxytocin: increased pressor effect and arrhythmogenicity of phenylephrine;
• Inhalation anesthetics (halothane, enflurane, methoxyflurane, isoflurane, chloroform): increased risk of developing severe ventricular and atrial arrhythmias;
• Nitrates: reducing their antianginal effect, reducing the pressor effect of phenylephrine, the risk of developing arterial hypotension;
• Thyroid hormones: synergistic effect of drugs and an increase in the associated risk of developing coronary insufficiency, especially in patients with coronary atherosclerosis;
• Alpha-blockers, phenothiazines: decreased hypertensive effect;
• Methylergometrine, doxapram, ergotamine, oxytocin, ergometrine: increased severity of vasoconstrictor action;
• Beta-blockers: decreased cardiac stimulating activity; when using reserpine there is a risk of developing arterial hypertension.

Analogs

Analogues of Mezaton are: Irifrin 2.5%, Nazol kids spray.

Terms and conditions of storage

Store at temperatures up to 25ºC. Do not expose to light. Keep away from children.

Shelf life – 3 years.